MFG-IRAP University of Pittsburgh.
The University of Pittsburgh is developing MFG-IRAP gene therapy for the potential treatment of arthritis. Phase II studies have commenced, including one trial in arthritis patients [225365]. A retrovirus (MFG-IRAP) is used in the ex vivo transfer of a cDNA encoding the human interleukin-1 receptor antagonist (IL-1Ra). The therapy is being tested in post-menopausal women, and involves the removal of some of their synovium, which is then transfected with the IRAP gene and reimplanted into the joint [188197]. A phase I rheumatoid arthritis trial of a therapy using the IL-1 antagonist gene therapy in synergy with soluble TNF alpha receptors was reported in March 1999 and was considered to be effective in producing an anti-arthritic effect [318398].
Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. Vijaykumar.Baragi@pfizer.com
V M
VM
Baragi
D000818:Animals; D018501:Antirheumatic Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D001168:Arthritis / Q000628:therapy*; D017690:Cell Transplantation; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D012190:Retroviridae / Q000737:chemistry
D018501:Antirheumatic Agents; D015507:Drugs, Investigational